Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines

Natalie S. Callander; Muhamed Baljevic; Kehinde Adekola; Larry D. Anderson; Erica Campagnaro; Jorge J. Castillo; Caitlin Costello; Srinivas Devarakonda; Noura Elsedawy; Matthew Faiman; Alfred Garfall; Kelly Godby; Jens Hillengass; Leona Holmberg; Myo Htut; Carol Ann Huff; Malin Hultcrantz; Yubin Kang; Sarah Larson; Michaela Liedtke; Thomas Martin; James Omel; Douglas Sborov; Kenneth Shain; Keith Stockerl-Goldstein; Donna Weber; Ryan A. Berardi; Rashmi Kumar; Shaji K. Kumar

doi:10.6004/jnccn.2022.0002

Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines

Natalie S. Callander, Muhamed Baljevic, Kehinde Adekola, Larry D. Anderson, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Michaela LiedtkeThomas Martin, James Omel, Douglas Sborov, Kenneth Shain, Keith Stockerl-Goldstein, Donna Weber, Ryan A. Berardi, Rashmi Kumar, Shaji K. Kumar

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.

Original language	English (US)
Pages (from-to)	8-19
Number of pages	12
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2022.0002
State	Published - Jan 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2022.0002

Cite this

Callander, N. S., Baljevic, M., Adekola, K., Anderson, L. D., Campagnaro, E., Castillo, J. J., Costello, C., Devarakonda, S., Elsedawy, N., Faiman, M., Garfall, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C. A., Hultcrantz, M., Kang, Y., Larson, S., ... Kumar, S. K. (2022). Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 20(1), 8-19. https://doi.org/10.6004/jnccn.2022.0002

@article{28986756ea2347ab822220343753c289,

title = "Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.",

author = "Callander, {Natalie S.} and Muhamed Baljevic and Kehinde Adekola and Anderson, {Larry D.} and Erica Campagnaro and Castillo, {Jorge J.} and Caitlin Costello and Srinivas Devarakonda and Noura Elsedawy and Matthew Faiman and Alfred Garfall and Kelly Godby and Jens Hillengass and Leona Holmberg and Myo Htut and Huff, {Carol Ann} and Malin Hultcrantz and Yubin Kang and Sarah Larson and Michaela Liedtke and Thomas Martin and James Omel and Douglas Sborov and Kenneth Shain and Keith Stockerl-Goldstein and Donna Weber and Berardi, {Ryan A.} and Rashmi Kumar and Kumar, {Shaji K.}",

note = "Funding Information: This activity is supported by educational grants from AstraZeneca; BeiGene; Exact Sciences; Gilead Sciences, Inc.; GlaxoSmithKline; Lantheus Medical Imaging Inc.; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Astellas. This activity is supported by an education grant from Astellas and Seagen Inc. This activity is supported by a medical education grant from Karyopharm{\textregistered} Therapeutics. This activity is supported through an Independent Medical Education grant from Merck & Co., Inc. Publisher Copyright: {\textcopyright} 2022 Harborside Press. All rights reserved.",

year = "2022",

month = jan,

doi = "10.6004/jnccn.2022.0002",

language = "English (US)",

volume = "20",

pages = "8--19",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "1",

}

Callander, NS, Baljevic, M, Adekola, K, Anderson, LD, Campagnaro, E, Castillo, JJ, Costello, C, Devarakonda, S, Elsedawy, N, Faiman, M, Garfall, A, Godby, K, Hillengass, J, Holmberg, L, Htut, M, Huff, CA, Hultcrantz, M, Kang, Y, Larson, S, Liedtke, M, Martin, T, Omel, J, Sborov, D, Shain, K, Stockerl-Goldstein, K, Weber, D, Berardi, RA, Kumar, R & Kumar, SK 2022, 'Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 20, no. 1, pp. 8-19. https://doi.org/10.6004/jnccn.2022.0002

TY - JOUR

T1 - Multiple Myeloma, Version 3.2022

T2 - Featured Updates to the NCCN Guidelines

AU - Callander, Natalie S.

AU - Baljevic, Muhamed

AU - Adekola, Kehinde

AU - Anderson, Larry D.

AU - Campagnaro, Erica

AU - Castillo, Jorge J.

AU - Costello, Caitlin

AU - Devarakonda, Srinivas

AU - Elsedawy, Noura

AU - Faiman, Matthew

AU - Garfall, Alfred

AU - Godby, Kelly

AU - Hillengass, Jens

AU - Holmberg, Leona

AU - Htut, Myo

AU - Huff, Carol Ann

AU - Hultcrantz, Malin

AU - Kang, Yubin

AU - Larson, Sarah

AU - Liedtke, Michaela

AU - Martin, Thomas

AU - Omel, James

AU - Sborov, Douglas

AU - Shain, Kenneth

AU - Stockerl-Goldstein, Keith

AU - Weber, Donna

AU - Berardi, Ryan A.

AU - Kumar, Rashmi

AU - Kumar, Shaji K.

N1 - Funding Information: This activity is supported by educational grants from AstraZeneca; BeiGene; Exact Sciences; Gilead Sciences, Inc.; GlaxoSmithKline; Lantheus Medical Imaging Inc.; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Astellas. This activity is supported by an education grant from Astellas and Seagen Inc. This activity is supported by a medical education grant from Karyopharm® Therapeutics. This activity is supported through an Independent Medical Education grant from Merck & Co., Inc. Publisher Copyright: © 2022 Harborside Press. All rights reserved.

PY - 2022/1

Y1 - 2022/1

N2 - The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.

AB - The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.

UR - http://www.scopus.com/inward/record.url?scp=85123267851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123267851&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2022.0002

DO - 10.6004/jnccn.2022.0002

M3 - Article

C2 - 34991075

AN - SCOPUS:85123267851

SN - 1540-1405

VL - 20

SP - 8

EP - 19

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -

Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this